As Affymetrix Tries to Salvage Deal, eBioscience Explores Other Options | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix said this week that it has released eBioscience from certain obligations under the terms of their proposed merger as the Santa Clara, Calif.-based array firm continues in its efforts to salvage the $330 million deal.

The company also disclosed a deal with a firm named Cellular Research, founded by Stephen Fodor, who also founded Affy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.